Stay updated with breaking news from Ashley Kaplowitz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CAMBRIDGE - Sage Therapeutics, Inc. announced today topline results from PRECEDENT, a double-blind, placebo-controlled Phase 2 study of the investigational oral medicine dalzanemdor in people with...
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q4 2023 Earnings Call Transcript February 14, 2024 Sage Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. Welcome to SAGE Therapeutics’ Fourth Quarter and Full Year 2023 Financial Results Conference Call. [Operator […]
ZURZUVAE, the first and only oral, once-daily, 14-day treatment course, has shown to provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3 for women with PPDPatient support program, ZURZUVAE For You, and financial assistance available to eligible women with PPD prescribed ZURZUVAEPatients...
The United States Adopted Name Council assigned the nonproprietary name of dalzanemdor to investigational SAGE-718, which is being studied for potential treatment of cognitive impairment...
Operator: Good morning. Welcome to Sage Therapeutics' Third Quarter 2023 Conference Call. [Operator Instructions].